Pro-inflammatory cytokines and their signaling

Pro-inflammatory cytokines are a broad class of signaling proteins, including Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), that are primarily secreted by activated macrophages and T-lymphocytes to mediate and amplify inflammatory responses [Dinarello, 2000, Chest]. These molecules bind to specific high-affinity cell-surface receptors, triggering intracellular signaling pathways such as the Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT) and Nuclear Factor-kappa B (NF-kB) pathways to regulate gene expression [O'Shea et al., 2013, NEJM]. While essential for host defense against pathogens, the chronic overproduction or dysregulation of these cytokines is a central driver in the pathogenesis of various inflammatory and autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis [Zhang & An, 2007, Int J Med Sci]. Therapeutic strategies often involve monoclonal antibodies to neutralize the cytokines themselves, receptor antagonists to block binding, or small molecule inhibitors to disrupt downstream signaling [Taylor et al., 2020, Nature Reviews Rheumatology]. Key signaling components like the JAK family of kinases serve as critical nodes that integrate signals from multiple cytokine receptors, making them high-value targets for broad-spectrum anti-inflammatory therapy [O'Shea et al., 2013, NEJM]. However, because these pathways are integral to normal immune surveillance, their inhibition is associated with significant safety concerns, most notably an increased susceptibility to opportunistic infections and potential malignancy [Kerschbaumer et al., 2020, Annals of the Rheumatic Diseases].

Other names

Pro-inflammatory cytokine signaling pathwayInflammatory cytokine cascadePro-inflammatory cytokine mediatorsCytokine-mediated inflammatory signaling

Therapeutic agents target this system through several distinct mechanisms: monoclonal antibodies and soluble receptors neutralize circulating cytokines (e.g., anti-TNF, anti-IL-6); receptor antagonists competitively block cytokine binding to their cognate receptors (e.g., IL-1Ra); and small-molecule inhibitors disrupt intracellular signal transduction by targeting kinases such as Janus kinases (JAKs) to prevent the activation of downstream transcription factors [Taylor et al., 2020, Nature Reviews Rheumatology; O'Shea et al., 2013, NEJM].